Bristol - Myers Squibb Company NYSE: BMY p. farmaceutyczny m.in. leki na raka

[slayer74]

wykres:
http://finance.yahoo.com/echarts?s=bmy+Interactive
https://stockcharts.com/h-sc/ui?s=bmy

Bristol-Myers Squibb Company NYSE: BMY - Amerykańska firma bio-farmaceutyczna założona w 1989 roku, mająca siedzibę w Nowym Jorku. Obecnie lider w leczeniu raka na świecie. Firma specjalizuje się w produkcji leków na receptę w kilku obszarach:
- rak
- HIV/AIDS
- choroba sercowo-naczyniowa
- cukrzyca
- zapalenie wątroby
- reumatoidalne zapalenie stawów
- zaburzenia psychiczne

Ostatnie istotne działania firmy:
- Przejęcie firmy Celegne w 2019 roku za 74mld $ (największa farmaceutyczne przejęcie w historii), tworząc największą firmę zajmującą się leczeniem raka na świecie!
- zwiększenie portfela onkologicznego i możliwość produkcji leków na raka krwi Revlimid i Imnovid
- przejęcie MyoKardia w 2020 roku za 13,1mld $
- zwiększenie portfela Kardiologicznego i złożenie aplikacji do FDA o zaakceptowane Mavacamten leku na objawowe HCM
- złożenie do FDA aplikacji leku Ide-cel na nowotwór układu krwiotwórczego (szpiczak mnogi), decyzja o akceptacji ma zapaść w Marcu 2021, według analityków Wallstreet będzie to najważniejsza decyzja w kwestii dopuszczenia jakiegokolwiek leku w tym roku!

Spółka wchodzi w skład indeksu S&P 100 i S&P 500

http://pl.wikipedia.org/wiki/Bristol-Myers_Squibb
http://en.wikipedia.org/wiki/Bristol-Myers_Squibb
dywidendy
https://finviz.com/quote.ashx?t=BMY
https://www.nasdaq.com/symbol/bmy/dividend-history
https://seekingalpha.com/symbol/BMY/dividends/scorecard

[slayer74]

ATechniczna - rekord wszech czasów

P/E 76

[slayer74]

ATechniczna - rekord wszech czasów

P/E 76

ATechniczna - rekord wszech czasów

[slayer74]

How Bristol-Myers Actually Won by Stopping a Clinical Study
http://247wallst.com/healthcare-busines ... cal-study/

[slayer74]

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors
http://247wallst.com/healthcare-busines ... investors/

[slayer74]

Bristol-Myers 'Is Back' and Could Soar Another 14%
https://www.thestreet.com/story/1449029 ... -soar.html

[slayer74]

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy
https://www.thestreet.com/markets/brist ... y-14751886

[slayer74]

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales
https://www.thestreet.com/investing/bri ... s-14757123

[slayer74]

Bristol-Myers Squibb Co. (BMY - Get Report) posted stronger-than-expected fourth quarter-earnings Thursday but pulled an application to the U.S. Food & Drug Administration for a blockbuster cancer drug combination in order to collect more data.

Bristol-Myers said profits for the three months ending in December came in at $94 cents a share, firmly ahead of the consensus estimate of 85 cents and up 38% from the same period last year. Group revenues, Bristol-Myers said, rose 10% to $5.973 billion, just ahead of the Street forecast of $5.95 billion.
...

https://www.thestreet.com/investing/ear ... n-14844064

[slayer74]

Bristol-Myers Looks Incredibly Cheap
Summary
BMY just posted solid Q2 results which included double-digit top- and bottom-line growth.

The company trades for just 10x earnings and offers a safe, 3.6% dividend yield.

The Celgene acquisition appears to be on track, and this move should add further gains to the company's bottom line in the near-term.

https://seekingalpha.com/article/428114 ... ngcom_feed

[slayer74]

Bristol-Myers Crushes Forecasts In Its First Post-Celgene Quarter

For the fourth quarter ended Dec. 31, Bristol-Myers earnings were $1.22 per share, minus certain items, on $7.95 billion in sales. Both topped the forecast of analysts polled by Zacks Investment Research for adjusted profit of 88 cents per share on $6.14 billion in sales.

On a year-over-year basis, Bristol-Myers earnings surged 30% and sales popped 33%. Earnings growth was last that bullish in December 2018. Sales haven't risen that much in years. That pop is likely due, in part, to Bristol-Myers Squibb's (BMY) acquisition of Celgene, which wrapped Nov. 20.

Chief Executive Giovanni Caforio called 2019 a "transformative year" for Bristol-Myers.

"We progressed our strategy through the acquisition of Celgene, delivered strong operational and financial performance and continued to drive important science for patients," he said in a written statement.

https://www.investors.com/news/technolo ... s-q4-2019/

[slayer74]

Jim Cramer Says Bristol-Myers Stock Is Huge Buying Opportunity

Bristol-Myers boosted its full-year profit outlook, as stronger sales of its Eliquis blood clotting treatment offset the continue slump in revenues from Opdivo.

Bristol-Myers said non-GAAP earnings for the three months ending in June were pegged at $1.63 per share, up 38.1% from the same period last year and firmly ahead of the Street consensus forecast of $1.48 per share. Group revenues, Bristol-Myers said, rose 61% to $10.13 billion, again topping analysts' forecasts of a $9.97 billion tally.

Looking into the final half of the year, Bristol-Myers said it sees non-GAAP earnings of $6.10 to $6.25 per share, compared to a prior forecast of $6.00 to $6.20, and revenues in the range of $40.5 billion to $42 billion, a modest increase from the lower end of its previous forecast.

“Our second-quarter results reflect the passion and focus of our employees, who continue to introduce new medicines, support patients with serious diseases and deliver strong results during the COVID-19 pandemic,” said CEO Giovanni Caforio.

“Our teams drove strong commercial execution while continuing to progress our integration initiatives. With several new product launches and the achievement of multiple milestones from our late-stage pipeline, I am confident that we are building a leading biopharma with a renewed portfolio of transformational medicines. Our financial flexibility and continued opportunities to invest in innovation position us well to deliver for the long-term,” he added.

https://www.thestreet.com/video/jim-cra ... pportunity

[slayer74]

Kolejna wielomiliardowa akwizycja Bristol Myers

TADEUSZ STASIUK opublikowano: dzisiaj, 05-10-2020, 13:34
Amerykański koncern farmaceutyczny Bristol Myers Squibb przejmie firmę MyoKardia w ramach transakcji o wartości około 13,1 mld USD, informuje Reuters.

Oferta Amerykanów powinni zadowolić udziałowców MyoKardia, gdyż gwarantuje im ponad 61-proc. premię względem kursu zamknięcia notowań z minionego piątku. Bristol płaci bowiem225 USD za akcję. Transakcja rozliczona ma być gotówkowo.

https://www.pb.pl/kolejna-wielomiliardo ... rs-1004441

[slayer74]

Bristol Myers Squibb hikes dividend by 8.9 percent. $BMY,

[slayer74]

Undervalued Dividend Growth Stock of the Week: Bristol-Myers Squibb (BMY)



https://dailytradealert.com/2021/01/10/ ... quibb-bmy/

https://www.youtube.com/watch?v=WPBmahh ... sAndIncome